Lenny has been fighting kidney cancer in one form or another since 2008. After doctors discovered a tumor in his kidney ten years ago, Lenny underwent several surgeries to remove tumor growths and eventually had his entire kidney removed. 

Unfortunately, Lenny's disease came back in 2013, and this time surgery was no longer an option. He now had an inoperable form of the disease that had spread to other parts of his body as well.

Lenny started on clinical trial of a targeted drug that helped to shrink his tumor dramatically. Lenny was also feeling good and experienced minimal side effects while on the trial.

When his disease returned in 2015, Lenny had additional treatment options at Dana-Farber. He started on a new form of therapy called immunotherapy. Immunotherapy harnesses the body's own immune system to recognize and destroy cancer cells, much the same way our immune system seeks out a virus or infection. Lenny's tumors have not grown since he has been on this new medication. 

While every day is challenge in some ways for Lenny, he maintains an upbeat and positive outlook. He calls Dr. Choueiri and his treatment team the best thing that ever happened to him.

Dr. Choueiri the lead investigator of multiple national and international phase one, two and three trials in GU cancers.

Dr. Choueiri is interested in developing novel therapies and biomarkers in GU malignancies, including kidney cancer. His research also focuses on epidemiology, diagnosis and treatment outcomes of GU cancers using large scale approaches such as meta-analyses from available published trials or national databases.